Two research teams independently reported in the Oct. 5, 2022, issues of Nature (Duke University) and Nature Biotechnology (Stanford University) on the development of RNA sensing technologies designed to target cell-specific RNA sequences to form a double-stranded RNA:RNA hybrid that is then edited by endogenous ADAR proteins to remove a stop codon and ultimately enabled to express any protein placed within the construct. The target design typically starts from single-cell RNA transcriptomics data that previously identified cell-specific RNA transcriptomics. Read More
Researchers at the University of Cincinnati have published data showing that in patients with dominantly inherited Alzheimer’s disease (AD)-causing mutations, high levels of soluble amyloid-β42 (Aβ42) in the cerebrospinal fluid (CSF) predicted a reduced risk of developing dementia over 3 years. Their work, which appeared in the Oct. 4, 2022, print issue of the Journal of Alzheimer’s Disease after earlier publication online, suggests that the problem with amyloid in AD may be a lack of soluble amyloid-β, rather than a surfeit of plaques. Read More
Topoisomerase I (topo I) and cyclooxygenase-2 (COX-2) are known targets in colon cancer, and Chinese scientists have sought dual topo I/COX-2 inhibitors to provide anticancer activity without the potential for side effects seen with combined therapy. Read More
Cabaletta Bio Inc. has announced CABA-201, a newly designed, fully human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain. Read More
It has been previously demonstrated that prepulse inhibition (PPI) is modulated by neurosteroids and in vivo research in mice has shown that PPI of the startle, a well-validated index of sensorimotor gating, is reduced by the neurosteroid allopregnanolone (AP). In recent work, a group of international researchers aimed to assess whether AP might mediate the PPI-disrupting effects of acute stress. Read More
Primary ovarian insufficiency (POI) is a clinical syndrome characterized by premature exhaustion of the resting pool of primordial follicles before the age of 40 years in women; the mechanism of follicular depletion is not well understood. Read More
Allorion Therapeutics Co. Ltd. has patented nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus. Read More
Shenzhen Forward Pharmaceutical Co. Ltd. has divulged estrogen receptor α (ERα) antagonists and/or degradation inducers reported to be useful for the treatment of cancer. Read More
Extracellular vesicles (EVs) are nanosized membrane vesicles released from a variety of cells that play important roles in cell-cell communication and which circulate in almost every body fluid, including blood, urine and cerebrospinal fluid (CSF). Read More
Medshine Discovery Inc. has presented furan fused ring-substituted glutarimides as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to androgen receptor-targeting moiety reported to be useful for the treatment of prostate cancer. Read More
Chiesi Farmaceutici SpA has synthesized Janus kinase inhibitors, particularly JAK1, JAK2, JAK3 and nonreceptor tyrosine-protein kinase TYK2 inhibitors, reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome. Read More
It is largely known that oral drug delivery for macromolecules is often limited by the degradative environment of the gastrointestinal tract. Researchers from the Massachusetts Institute of Technology and their collaborators have presented Robocap, an oral mucus-clearing drug-delivery capsule that enhances the gastrointestinal absorption of drugs. Read More
Suzhou Zion Pharma Technology Co. Ltd. has divulged serine-protein kinase ATM (ataxia telangiectasia mutated) inhibitors reported to be useful for the treatment of cancer. Read More